55 results about "Amino acid transporter" patented technology

An object of the present invention is to provide a monoclonal antibody which is useful for treating or diagnosing a disease relating to system ASC amino acid transporter 2 (hereinafter, referred to as “ASCT2”) or a method using the antibody. The present invention provides a monoclonal antibody which specifically recognizes a native three-dimensional structure of an extracellular region of ASCT2 and binds to the extracellular region, or an antibody fragment thereof; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which contains the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent using the antibody or the antibody fragment thereof, and a diagnostic agent using the antibody or the antibody fragment thereof.

The invention discloses application of an amino acid transporter gene OsAAP3 in rice seed selection, and belongs to the technical field of genetic engineering. An amino acid sequence of encoded protein of the gene OsAAP3 is specified in SEQ ID NO.1, and a Cdna sequence is specified in SEQ ID NO.2. According to the application of the amino acid transporter gene OsAAP3 in rice seed selection, by constructing a rice plant which is interfered by the gene OsAAP3, and constructing a rice plant which is over-expressed by the gene OsAAP3, it is discovered that reduction of genetic expression of the gene OsAAP3 can increase tiller number of the rice and spike number in each rice plant, and therefore the gene OsAAP3 can be used in rice seed selection for increasing the rice yield. The gene OsAAP3 has important application value in expounding influence of amino acid transportation on growth and development process of the plant.

Disclosed are pharmaceutical compositions and methods of treating hepatoma by administering to patients or other populations of cells agents that selectively inhibit the uptake of glutamine by hepatocarcinoma cells, causing the concomitant apoptosis of hepatocarcinoma cells. Preferred agents target the amino acid transporter B0 (ATB0) protein for inhibition. Disclosed are antisense polynucleotides that reduce the expression of ATB0 in hepatocarcinoma cells, causing those cells to reduce the uptake of glutamine and subsequently undergo selective apoptosis.

A human antibody or a functional fragment thereof having specific binding ability to CD98 which is derived from the cell membrane of cancer cells and is in the form of a complex with a protein having an amino acid transporter activity (for example, LAT1) is disclosed. This antibody binds to CD98 in the form of a dimer with LAT1 on the surface of cancer cells, specifically attacks cancer cells expressing CD98 via the immune system by ADCC or CDC, and further inhibits amino acid uptake of the cancer cells via LAT1, to suppress growth of the cancer cells. Accordingly, a preventive and therapeutic agent for cancer comprising this antibody or a fragment thereof, which acts on various cancers, is specific to cancer, and causes no side effect, is provided.

An object of the present invention is to provide a monoclonal antibody which is useful for treating or diagnosing a disease relating to system ASC amino acid transporter 2 (ASCT2) or a method using the antibody. The present invention provides a monoclonal antibody which specifically recognizes a native three-dimensional structure of an extracellular region of system ASC amino acid transporter 2 (ASCT2) and binds to the extracellular region, or an antibody fragment thereof; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which contains the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent using the antibody or the antibody fragment thereof, and a diagnostic agent using the antibody or the antibody fragment thereof.

The invention relates to an amphiphilic targeting functional material based on high expression of tumor amino acid transporter ATB<0, +> and an application of nano preparation modified by the same in targeting therapy of tumor. In the amphiphilic targeting functional material, stearic acid (SA) serves as a hydrophobic end while amino acid (AA) serves as a target end, and the middle connection bridge is polyethylene glycol (PEG). The nano preparation modified by the amphiphilic targeting functional material can remarkably improve the tumor targeting ability of an active drug. The characteristics of the invention are that the targeting functional material is easy to prepare, and the nano preparation modified by the targeting functional material can actively target the amino acid transporter ATB<0, +> with high expression of tumor, has high biocompatibility and can remarkably improve the drug therapeutic effect.

The invention provides isolated nucleic acids molecules, designated 38594, 57312, 53659, 57250, 63760, 49938, 32146, 57259, 67118, 67067, 62092, FBH58295FL, 57255, and 57255alt nucleic acid molecules, which encode transporter molecules, including sugar transporters, organic anion transporters, amino acid transporters, and phospholipid transporters. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 38594, 57312, 53659, 57250, 63760, 49938, 32146, 57259, 67118, 67067, 62092, FBH58295FL, 57255, and 57255alt nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a 38594, 57312, 53659, 57250, 63760, 49938, 32146, 57259, 67118, 67067, 62092, FBH58295FL, 57255, and 57255alt gene has been introduced or disrupted. The invention still further provides isolated 38594, 57312, 53659, 57250, 63760, 49938, 32146, 57259, 67118, 67067, 62092, FBH58295FL, 57255, and 57255alt polypeptides, fusion polypeptides, antigenic peptides and anti-38594, 57312, 53659, 57250, 63760, 49938, 32146, 57259, 67118, 67067, 62092, FBH58295FL, 57255, and 57255alt antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

A human antibody or a functional fragment thereof having specific binding ability to CD98 which is derived from the cell membrane of cancer cells and is in the form of a complex with a protein having an amino acid transporter activity (for example, LAT1) is disclosed. This antibody binds to CD98 in the form of a dimer with LAT1 on the surface of cancer cells, specifically attacks cancer cells expressing CD98 via the immune system by ADCC or CDC, and further inhibits amino acid uptake of the cancer cells via LAT1, to suppress growth of the cancer cells. Accordingly, a preventive and therapeutic agent for cancer comprising this antibody or a fragment thereof, which acts on various cancers, is specific to cancer, and causes no side effect, is provided.

The present disclosure relates to erythroid cells that have been engineered to express a homocysteine reducing polypeptide, or a variant thereof, or a homocysteine degrading polypeptide, or a variant thereof. The engineered erythroid cells may further comprise an amino acid transporter, for example a homocysteine transporter or a serine transporter, or a cystathionine degrading polypeptide. The engineered erythroid cells of the present disclosure are useful in reducing the level of homocysteine in a subject. The engineered erythroid cells of the present disclosure are further useful in methods of treating homocystinuria.

A human N system amino acids transporter (hNAT-1), its coding sequence, its preparing process and its use are disclosed. The nucleic acid and antisence strand or fragment of said hNAT-1 can be used to prepare the probe for detecting the abnormality of hNAT-1 gene. The hNAT-1 protein or its suppressor can be used to prepare medicines or reagent kit for regulating the bioactivity of living body, especially the liver cells.

A human antibody or a functional fragment thereof having specific binding ability to CD98 which is derived from the cell membrane of cancer cells and is in the form of a complex with a protein having an amino acid transporter activity (for example, LAT1) is disclosed. This antibody binds to CD98 in the form of a dimer with LAT1 on the surface of cancer cells, specifically attacks cancer cells expressing CD98 via the immune system by ADCC or CDC, and further inhibits amino acid uptake of the cancer cells via LAT1, to suppress growth of the cancer cells. Accordingly, a preventive and therapeutic agent for cancer comprising this antibody or a fragment thereof, which acts on various cancers, is specific to cancer, and causes no side effect, is provided.

The present invention is based in part on the discovery of brown and white fat cell specific surface markers. It has been found that the small amino acid transporter Slca10 / Asc1 is a specific surface marker for white adipocytes and that the ligand-gated ion channel P2X5 and the small amino acid transporter Slc36a2 are specific surface markers for brown adipocytes. Having identified these specific white and brown cell surface markers, the present invention provides compositions and methods suitable for the targeting of any number of agents to a white or brown adipose tissue and the identification and isolation of white or brown adipocytes for any number of uses including therapeutic, screening and diagnostic purposes.

An object of the present invention is to provide a monoclonal antibody which is useful for treating or diagnosing a disease relating to system ASC amino acid transporter 2 (ASCT2) or a method using the antibody. The present invention provides a monoclonal antibody which specifically recognizes a native three-dimensional structure of an extracellular region of system ASC amino acid transporter 2 (ASCT2) and binds to the extracellular region, or an antibody fragment thereof; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which contains the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent using the antibody or the antibody fragment thereof, and a diagnostic agent using the antibody or the antibody fragment thereof.

The present invention has revealed the compounds transportable by ATB<0+>. Based on the information about these compounds, drugs transportable by ATB<0,+> may be designed, produced and screened. Such drugs may serve to treat and / or prevent the diseases in which NOS, phenylglycine, carnitine, D-amino NOS, phenylglycine, carnivolved. The ATB<0,+> gene may be administered to patients to be used for gene therapy of the diseases as described above.

A novel amino acid transporter molecule mediating transportation of amino acids, which are nutrients essentially required in the survival and proliferation of various normal cells constituting a living body and various pathology-associated abnormal cells such as tumor cells, into cells and being expressed specifically in tumor cells compared with normal cells; and drugs for treating various pathogenic conditions such as tumor (cancer) which are obtained by identifying and isolating the above amino acid transporter molecule and identifying a substance capable of inhibiting the biological activity and / or expression of this molecule. Intensive studies were made to identify a tumor cell membrane surface molecule associating or interacting with a cell membrane surface 4F2hc molecule seemingly playing an important role in the activation of an unknown amino acid transporter. As a result, a gene encoding the novel amino acid transporter molecule, which mediates the incorporation of various neutral amino acids, various drugs or physiological substances into cells, has been found out and a substance capable of inhibiting the incorporation of amino acids via this molecule and thus inhibiting the proliferation of tumor cells has been also found out.

A novel amino acid transporter molecule mediating transportation of amino acids, which are nutrients essentially required in the survival and proliferation of various normal cells constituting a living body and various pathology-associated abnormal cells such as tumor cells, into cells and being expressed specifically in tumor cells compared with normal cells; and drugs for treating various pathogenic conditions such as tumor (cancer) which are obtained by identifying and isolating the above amino acid transporter molecule and identifying a substance capable of inhibiting the biological activity and / or expression of this molecule. Intensive studies were made to identify a tumor cell membrane surface molecule associating or interacting with a cell membrane surface 4F2hc molecule seemingly playing an important role in the activation of an unknown amino acid transporter. As a result, a gene encoding the novel amino acid transporter molecule, which mediates the incorporation of various neutral amino acids, various drugs or physiological substances into cells, has been found out and a substance capable of inhibiting the incorporation of amino acids via this molecule and thus inhibiting the proliferation of tumor cells has been also found out.

The compounds of the invention are inhibitors of excitatory amino acid transporters (EAAT) that penetrate the blood-brain barrier to access the central nervous system. The compounds of the invention follow the structural formula:or a salt, ester or prodrug thereof, wherein X is a halogen, such as fluorine, or a radionuclide, such as fluorine-18. The compounds and methods described herein can be used for the treatment of, e.g., neurodegenerative disorders (e.g., amyotrophic lateral sclerosis), ischemia, spinal cord injury, and traumatic brain injury in a patient (e.g., a human). The invention further provides compounds and methods for the synthesis and use of radiographic tracers to diagnose and follow the progression of such disorders.

The invention relates to an anti-tumor medicament namely an amino acid-doxorubicin derivative, a preparation method of the anti-tumor medicament, and an application of the anti-tumor medicament. Specifically, the invention relates to an amino acid-doxorubicin derivative with a structure shown in a formula I, pharmaceutically-acceptable salts of the amino acid-doxorubicin derivative, a medicament composition adopting the compound and the pharmaceutically-acceptable salts of the compound as active and effective components, a preparation method of the amino acid-doxorubicin derivative, the pharmaceutically-acceptable salts and the medicament composition, and an application of the amino acid-doxorubicin derivative, the pharmaceutically-acceptable salts and the medicament composition in treating cancers (liver cancer, acute leukemia, malignant lymphoma, breast cancer, ovarian cancer, soft tissue sarcoma, osteogenic sarcoma, rhabdomyosarcoma, kidney cancer, colon cancer, bladder cancer, thyroid cancer, prostatic cancer, testicular cancer, gastric cancer and the like), and preferentially treating the cancers (liver cancer, colon cancer, breast cancer, prostatic cancer and the like) with over-expressed L-type amino acid transporters (LATs).

The invention discloses application of specific genes of staphylococcus epidermidis. The genes are Amino acid transporter LysE genes, and the Genbank login number is 3240523. Through the primer, whether the Amino acid transporter LysE genes exist in a sample or not is detected through a polymerase chain reaction, and then whether the staphylococcus epidermidis exists in the sample or not is determined. The staphylococcus epidermidis can be detected through the specific genes fast, easily, conveniently and accurately.

The invention discloses a sulfonyl fluoride compound. Compared with reported PET imaging agents for targeted amino acid transporter, fibroblast activating protein, vesicular monoamine transporter 2, serotonin receptor and prostate specific membrane antigen protein change related diseases, the series of sulfonyl fluoride compounds designed and synthesized by the invention have the advantages of simple labeling conditions, high yield and high affinity. The invention belongs to the technical field of radiopharmaceutical chemistry and nuclear medicine.

An object of the present invention is to provide a monoclonal antibody which is useful for treating or diagnosing a disease relating to system ASC amino acid transporter 2 (hereinafter, referred to as “ASCT2”) or a method using the antibody. The present invention provides a monoclonal antibody which specifically recognizes a native three-dimensional structure of an extracellular region of ASCT2 and binds to the extracellular region, or an antibody fragment thereof; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which contains the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent using the antibody or the antibody fragment thereof, and a diagnostic agent using the antibody or the antibody fragment thereof.

A novel amino acid transporter molecule mediating transportation of amino acids, which are nutrients essentially required in the survival and proliferation of various normal cells constituting a living body and various pathology-associated abnormal cells such as tumor cells, into cells and being expressed specifically in tumor cells compared with normal cells; and drugs for treating various pathogenic conditions such as tumor (cancer) which are obtained by identifying and isolating the above amino acid transporter molecule and identifying a substance capable of inhibiting the biological activity and / or expression of this molecule. Intensive studies were made to identify a tumor cell membrane surface molecule associating or interacting with a cell membrane surface 4F2hc molecule seemingly playing an important role in the activation of an unknown amino acid transporter. As a result, a gene encoding the novel amino acid transporter molecule, which mediates the incorporation of various neutral amino acids, various drugs or physiological substances into cells, has been found out and a substance capable of inhibiting the incorporation of amino acids via this molecule and thus inhibiting the proliferation of tumor cells has been also found out.

The present invention includes inhibitors of the amino acid transporter ATB0,+ and methods of uses thereof.

The present invention includes inhibitors of the amino acid transporter ATB0,+ and methods of uses thereof.

Disclosed are methods for diagnosing CAT1-related diseases, wherein the methods include detecting CAT1 in a cell by a BLV.RBD ligand, or a variant or a fragment thereof. Also disclosed is a BLV.RBD ligand, or a variant or a fragment thereof for use in the treatment of CAT1-related diseases and / or BLV infections.

The invention provides a carrier-free protein intracellular delivery prodrug as well as a preparation method and application thereof. The carrier-free protein intracellular delivery prodrug is a carrier-free protein intracellular delivery system which is transferred through L-type amino acid transporter protein 1 (LAT1). The delivery system can directly deliver proteins with different charges / molecular weights into cells to prevent inclusion of endosomes / lysosomes and maintain protein activity, has excellent tumor targeting property, and reduces toxic and side effects. The delivery system is the first case of transmembrane transporter mediated carrier-free protein prodrug intracellular transport, and highly sensitive and highly selective regulation and control of protein activity in tumor cells are realized. The simple and efficient technology provides a new strategy for potential clinical application of anti-tumor protein drugs.

The invention belongs to the technical field of plant gene engineering, and discloses a tobacco amino acid transporter gene NtTAT and a purpose thereof. The contents comprise cloning on the amino acidtransporter gene NtTAT, building on an NtTAT gene interference carrier, expression features after NtTAT gene interference, influence on the tobacco leaf amino acid content, and amino acid content determination on homozygous transgenic later generations. In NtTaT interference homozygous plants, five kinds of amino acids (valine, proline, threonine, phenylalanine and the like) realize the obvious amino acid content increase, wherein the change of the proline is greatest; the increase is nearly 13 times; the contents of valine, threonine and phenylalanine are increased; the NtTAT influences theamino acid metabolism gene through the amino acid transportation capability change; the amino acid content of valine, proline, threonine, phenylalanine and the like in tobacco leaves is improved; andthe quality of the tobacco leaves is further improved.

The invention relates to a method for effectively intervening diabetes mellitus by using an L-type amino acid transporter inhibitor or antagonist, and particularly provides application of the L-type amino acid transporter inhibitor or antagonist to preparation of a composition or a preparation, and the composition or the preparation is used for preventing and / or treating diabetes mellitus. And the quantity of pancreatic beta cells can be improved. It is found for the first time that the L-type amino acid transporter inhibitor or antagonist can effectively reduce fasting blood glucose of mammals and can effectively treat diabetes mellitus.

The invention belongs to the field of tobacco genetic engineering, in particular to tobacco transcription factor genes NtFAMA and its application patent application. The base sequence of the gene is shown in SEQ ID NO.1. Tobacco transcription factor gene NtFAMA It consists of 287 amino acid residues, of which the amino acid transporter domain at the 91-142nd amino acid is conserved. This protein is related to the content of chlorogenic acid in plant leaves. After reducing the expression of this protein, the content of chlorogenic acid in leaves is significantly increased. The present invention is directed to specific tobacco transcription factors by NtFAMA Preliminary research on , found that it was highly correlated with the content of chlorogenic acid in tobacco, and after the gene was silenced, the content of chlorogenic acid in tobacco was significantly increased. Based on this characteristic, it can provide a certain application basis and reference for the cultivation of new tobacco varieties with reasonable chlorogenic acid content.

The invention discloses a preparation method of a carp amino acid transporter transport subunit rBAT rabbit antiserum. A key point of a technical scheme provided by the invention lays in that the preparation method of carp amino acid transporter transport subunit rBAT rabbit antiserum comprises the following steps: (1) cloning a carp intestinal amino acid transporter transport subunit rBAT gene; (2) constructing gene engineering strains of rBAT; (3) conducting inducible expression and identifying the gene engineering strains of amino acid transporter transport subunit rBAT; (4) preparing an amino acid transporter transport subunit rBAT antigen; (5) immunizing rabbits; (6) collecting a blood sample and determining titer of the carp intestinal amino acid transporter transport subunit rBAT; (7) collecting blood of carotid artery and preparing antiserum amino acid transporter transport subunit rBAT rabbit antiserum; and (8) detecting by an immunohistochemical method. The invention adopts partial gene fragment expressing a transmembrane protein and having an antigenic determinant as an antigen protein to substitute a full-length gene, and solves the problem that the transmembrane protein can not be expressed.